Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

Table 2 Changes in primary and secondary histologic outcomes after 6 mo of treatment with sitagliptin vs placebo

	Placebo (n = 6)			Sitagliptin (n = 6)			Difference
	Baseline	Post-treatment1	P value	Baseline	Post-treatment1	P value	(95%CI)	P value
Primary outcome
Fibrosis	2.2 ± 0.8	2.0 ± 1.0	0.85	2.2 ± 1.0	2.4 ± 1.1	0.85	0.4 (-0.98, 1.78)	0.82
Secondary outcomes
NAS	4.2 ± 1.5	3.8 ± 1.9	0.50	3.8 ± 0.8	3.4 ± 1.5	0.85	0.2 (-1.62, 2.02)	1.00
Steatosis	1.8 ± 0.8	1.6 ± 0.9	0.62	1.8 ± 0.8	1.4 ± 0.9	0.55	0 (-1.08, 1.08)	0.91
Hepatocyte ballooning	1.2 ± 0.4	1.4 ± 0.9	0.89	1.0 ± 0	0.8 ± 0.4	0.36	-0.40 (-1.05, 0.25)	0.23
Lobular inflammation	1.2 ± 0.4	0.8 ± 0.4	0.22	1.0 ± 0	1.2 ± 0.4	0.36	0.60 (-0.13, 1.33)	0.12

¹Data only available for 5 subjects. Data are presented as mean ± SD. NAS: Non-alcoholic fatty liver disease activity score.